ReviewCancer metastasis reviews2026
Understanding cachexia and muscle dysfunction in the context of metastatic breast cancer.
Review in Cancer metastasis reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cancer cachexia significantly impacts the quality of life of cancer patients, predicting therapy response and survival. Cachexia prevalence and severity increases over the course of disease progression, affecting up to 80% of patients with metastatic cancer. Despite this, cachexia is relatively understudied in the context of metastatic breast cancer, despite it affecting a significant proportion of patients with this common cancer. In this review we highlight the relative prevalence of cachexia in breast cancer, with 25% of all patients and up to half of those with metastatic disease impacted. Given the metastatic distribution pattern of breast cancer (e.g. high rates of bone metastases), we reviewed the unique systemic and local muscle cues leading to cachexia in this context and have reviewed areas for further investigation. Furthermore, anti-cancer therapies also contribute to cachexia progression. Recently, novel mouse models for study of cachexia in breast cancer have been developed. These models can further the field's understanding of cachexia in metastatic cancer patients and aid in the development of anti-cachectic agents. However, it is important that these models accurately recapitulate human disease. In this review we provide an appraisal of the relative utility of the currently available models. Overall, this review highlights that understanding cachexia in the context of breast cancer and metastasis may uncover novel mechanisms to target this condition, thereby improving the quality of life and survival prospects of metastatic cancer patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.